At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
Etanercept +1 moredrug
Likely dose
Etanercept 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Etanercept in Patients With the Metabolic Syndrome (II)
In Brief
A clinical study evaluating Etanercept and Placebo for Metabolic Syndrome. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This study will investigate whether etanercept will result in improved inflammatory indices, glucose tolerance and endothelial function in patients with the metabolic syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome
CountriesUnited States
CollaboratorsAmgen
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedDec 2006
Primary CompletionSep 2009
TodayJul 2026
First PostedDec 19, 2006
Enrollment StartDec 1, 2006
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.5 years ago
Interventions
Etanerceptdrug
50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months
Placebodrug
50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months